Search Results - "Bebernitz, Gregory"
-
1
Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes
Published in Journal of medicinal chemistry (08-10-2009)“…Type 2 diabetes is a polygenic disease which afflicts nearly 200 million people worldwide and is expected to increase to near epidemic levels over the next…”
Get full text
Journal Article -
2
Avoidance of the Ames test liability for aryl–amines via computation
Published in Bioorganic & medicinal chemistry (15-05-2011)“…Aryl–amines are commonly used synthons in modern drug discovery, however a minority of these chemical templates have the potential to cause toxicity through…”
Get full text
Journal Article -
3
The Effect of 1,3-Diaryl-[1H]-pyrazole-4-acetamides on Glucose Utilization in ob/ob Mice
Published in Journal of medicinal chemistry (02-08-2001)“…This article provides evidence of a new class of compounds, 1,3-diaryl-[1H]-pyrazole-4-acetamides, initially identified from their ability to increase glucose…”
Get full text
Journal Article -
4
The impact of fatty acid oxidation on energy utilization: targets and therapy
Published in Current pharmaceutical design (01-06-2002)“…Utilization of fat as a long-term energy storage vehicle is crucial for the maintenance of cellular metabolism and is under intricate and many times redundant…”
Get more information
Journal Article -
5
Anilides of (R)-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase
Published in Journal of medicinal chemistry (01-06-2000)“…The optimization of a series of anilide derivatives of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase…”
Get full text
Journal Article -
6
Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation
Published in Bioorganic & medicinal chemistry letters (01-04-2023)“…[Display omitted] Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a significant risk factor for ischemic stroke and heart failure. Marketed…”
Get full text
Journal Article -
7
Reduction in Glucose Levels in STZ Diabetic Rats by 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid: A Prodrug Approach for Targeting the Liver
Published in Journal of medicinal chemistry (15-02-2001)“…The overproduction of glucose by the liver in NIDDM patients markedly contributes to their fasting hyperglycemia and is a direct consequence of the increased…”
Get full text
Journal Article -
8
-
9
Hypoglycemic Prodrugs of 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid
Published in Journal of medicinal chemistry (14-01-1999)“…SAH 51-641 (1) is a potent hypoglycemic agent, which acts by inhibiting hepatic gluconeogenesis. It is a prodrug of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid…”
Get full text
Journal Article -
10
Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960
Published in European journal of pharmacology (05-09-2013)“…Glucokinase (GK) acts as a glucose sensor by facilitating glucose phosphorylation into glucose-6-phosphate (G6P) in the liver and pancreas, the two key target…”
Get full text
Journal Article -
11
BACE1/2 INHIBITION DOES NOT REGULATE PANCREATIC BETA CELL FUNCTION AND MASS IN MICE
Published in Alzheimer's & dementia (01-07-2014)Get full text
Journal Article -
12
P2‐059: BACE1/2 INHIBITION DOES NOT REGULATE PANCREATIC BETA CELL FUNCTION AND MASS IN MICE
Published in Alzheimer's & dementia (01-07-2014)Get full text
Journal Article -
13
(R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides Are Orally Active Inhibitors of Pyruvate Dehydrogenase Kinase
Published in Journal of medicinal chemistry (29-07-1999)Get full text
Journal Article -
14
( R )-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides Are Orally Active Inhibitors of Pyruvate Dehydrogenase Kinase
Published in Journal of medicinal chemistry (29-07-1999)Get full text
Journal Article